Is Choline Fenofibrate Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Choline Fenofibrate? Is Choline Fenofibrate safe for nursing mother and child? Does Choline Fenofibrate extracts into breast milk? Does Choline Fenofibrate has any long term or short term side effects on infants? Can Choline Fenofibrate influence milk supply or can Choline Fenofibrate decrease milk supply in lactating mothers?
Choline Fenofibrate lactation summary
- DrLact safety Score for Choline Fenofibrate is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of Choline Fenofibrate may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that Choline Fenofibrate may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of Choline Fenofibrate low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using Choline Fenofibrate We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Choline Fenofibrate usage in lactation
Fenofibrate, like other fibrates, decreases elevated blood lipids (triglycerides and cholesterol) by increasing the activity of lipases that catabolize triglyceride-rich lipoproteins and slightly decreasing cholesterol biosynthesis (AEMPS 2017, BGP 2015, Miller 1998). In general, fibrates have a discrete effect on the increase of high density lipoprotein (HDL) concentration and the reduction of low density lipoprotein (LDL). Since the last update we have not found published data in relation to breastfeeding. Its high binding to plasma proteins makes it unlikely it will pass into breast milk. Cholesterol levels in milk are very stable even in hypercholesterolemic women and are not severely affected by diet or nutritional status of the mother, suggesting that 3 is synthesized, at least in part, in the mammary gland (Lawrence 2016, p 289-90).It is not probable therefore, but it is not known if the fibrates are able to alter the lipid composition of the milk. Infants need to ingest large amounts of cholesterol, as it is critical to the proper development of the nervous system, cell membranes and is a precursor of several hormones and vitamins. Until there is more data in relation to breastfeeding, it is prudent to avoid using it, at least while breastfeeding exclusively. Suspending the pharmacological treatment of hyperlipidemia during breastfeeding is not likely to alter the long-term outcome of the disease, especially when breastfeeding can be considered therapeutic (Lawrence 2016, p.393). It is advisable to follow a lipid-lowering diet. In case of administering a fibrate during breastfeeding it is advisable to choose those with a shorter half-life: bezafibrate, gemfibrozil.